Unknown

Dataset Information

0

High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts.


ABSTRACT: SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM+IgG+, 9.0% IgM+IgG-, and 5.0% IgM-IgG+). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM+IgG-. These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection.

SUBMITTER: Naranbhai V 

PROVIDER: S-EPMC7499676 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8312903 | biostudies-literature
| S-EPMC8926102 | biostudies-literature
| S-EPMC7877494 | biostudies-literature
| S-EPMC8063076 | biostudies-literature
| S-EPMC9784013 | biostudies-literature
| S-EPMC10148621 | biostudies-literature
| S-EPMC9959557 | biostudies-literature
| S-SCDT-10_1038-S44318-024-00061-0 | biostudies-other
| S-EPMC9666986 | biostudies-literature
| S-EPMC8656675 | biostudies-literature